Extended dosing of monoclonal antibodies in multiple sclerosis
Research output: Contribution to journal › Review › Research › peer-review
Standard
Extended dosing of monoclonal antibodies in multiple sclerosis. / van Kempen, Zoé L.E.; Toorop, Alyssa A.; Sellebjerg, Finn; Giovannoni, Gavin; Killestein, Joep.
In: Multiple Sclerosis Journal, Vol. 28, No. 13, 2022, p. 2001-2009.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Extended dosing of monoclonal antibodies in multiple sclerosis
AU - van Kempen, Zoé L.E.
AU - Toorop, Alyssa A.
AU - Sellebjerg, Finn
AU - Giovannoni, Gavin
AU - Killestein, Joep
N1 - Publisher Copyright: © The Author(s), 2021.
PY - 2022
Y1 - 2022
N2 - Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.
AB - Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, “no evidence of MS disease activity” is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-α4β1-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.
KW - extended dosing
KW - monoclonal antibodies
KW - Multiple sclerosis
KW - personalized dosing
U2 - 10.1177/13524585211065711
DO - 10.1177/13524585211065711
M3 - Review
C2 - 34949134
AN - SCOPUS:85122076148
VL - 28
SP - 2001
EP - 2009
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
IS - 13
ER -
ID: 330398740